Search

Your search keyword '"HemispheRx BioPharma Inc. -- Product development"' showing total 72 results
Start Over Descriptor "HemispheRx BioPharma Inc. -- Product development"
72 results on '"HemispheRx BioPharma Inc. -- Product development"'

1. Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx' Ampligen and Pembrolizumab

Subjects
HemispheRx BioPharma Inc. -- Product development, Merck & Company Inc. -- Product development, Pharmaceutical industry -- Product development, Breast cancer, Clinical trials, Pembrolizumab, Parks, Biological products industry, Cancer metastasis, General interest, News, opinion and commentary, Ampligen (Medication)
Abstract

OCALA: Hemispherx Biopharma, Inc. has issued the following news release: Hemispherx today announced active initiation of a clinical trial sponsored by Roswell Park Comprehensive Cancer Center (Roswell Park) in Buffalo, [...]

Published
2019

2. Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx' Ampligen and Pembrolizumab

Subjects
Merck & Company Inc. -- Product development, HemispheRx BioPharma Inc. -- Product development, Pharmaceutical industry -- Product development, Breast cancer, Clinical trials, Pembrolizumab, Parks, Cancer metastasis, Banking, finance and accounting industries, Business, Ampligen (Medication)
Abstract

OCALA, Apr 02, 2019 (GLOBE NEWSWIRE via COMTEX) -- (NYSE American: HEB) -- Hemispherx today announced active initiation of a clinical trial sponsored by Roswell Park Comprehensive Cancer Center (Roswell [...]

Published
2019

3. Hemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center to Study Ampligen in Combination with Checkpoint Inhibitors in a Phase IIa Study in Urothelial Carcinoma, Renal Cell Carcinoma and Melanoma

Subjects
HemispheRx BioPharma Inc. -- Product development, Clinical trials, Cancer research, Parks -- United States, Melanoma, Renal cell carcinoma, Biological products industry -- Product development, General interest, News, opinion and commentary, Ampligen (Medication)
Abstract

Pennsylvania: Hemispherx Biopharma, Inc. has issued the following press release: Hemispherx Biopharma, Inc. (NYSE American: HEB) announces the signing of a clinical trial agreement with Roswell Park Comprehensive Cancer Center [...]

Published
2018

4. Hemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center to Study Ampligen in Combination with Checkpoint Inhibitors in a Phase IIa Study in Urothelial Carcinoma, Renal Cell Carcinoma and Melanoma

Subjects
HemispheRx BioPharma Inc. -- Product development, Clinical trials, Cancer research, Parks -- United States, Melanoma, Renal cell carcinoma, Biological products industry -- Product development, Banking, finance and accounting industries, Business, Ampligen (Medication)
Abstract

OCALA, Fla., Oct 10, 2018 (GLOBE NEWSWIRE via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces the signing of a clinical trial agreement with Roswell Park Comprehensive Cancer Center [...]

Published
2018

5. Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen(r) Phase III Trial in Patients with CFS/ME

Subjects
HemispheRx BioPharma Inc. -- Product development, Clinical trials, Biological products industry -- Product development, General interest, News, opinion and commentary, Ampligen (Medication)
Abstract

Philadelphia: Hemispherx BioPharma, Inc. has issued the following press release: Hemispherx Biopharma (NYSE:HEB) ('Hemispherx' or the 'Company') announced today that a retrospective analysis of the AMP-516 Phase III trial of [...]

Published
2016

6. Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen(R) Phase III Trial in Patients with CFS/ME

Subjects
HemispheRx BioPharma Inc. -- Product development, Clinical trials, Chronic fatigue syndrome -- Care and treatment, Biological products industry -- Product development, Banking, finance and accounting industries, Business, Alferon N (Medication), Ampligen (Medication)
Abstract

PHILADELPHIA, Oct 31, 2016 (GLOBE NEWSWIRE via COMTEX) -- 51% of patients in the high responder subset receiving Ampligen vs. 18% of placebo patients demonstrated improvement of at least 25% [...]

Published
2016

7. Hemispherx Biopharma Conducts an Interview with The Wall Street Transcript

Subjects
HemispheRx BioPharma Inc. -- Product development, Interferon -- Product development, Biological products industry -- Product development, Banking, finance and accounting industries, Business, Alferon N (Medication), Ampligen (Medication)
Abstract

PHILADELPHIA, Aug 15, 2016 (GLOBE NEWSWIRE via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the 'Company' or 'Hemispherx') has posted the transcript of The Wall Street Transcript interview with Thomas [...]

Published
2016

8. Hemispherx Biopharma Inc

Subjects
HemispheRx BioPharma Inc. -- Product development, Chronic fatigue syndrome -- Product development, Pharmaceutical industry -- Product development, Business, Business, regional, Ampligen (Medication) -- Usage
Abstract

Hemispherx Biopharma Inc. of Philadelphia announced that an application for Ampligen as a treatment for chronic fatigue syndrome filed by its sister company, Hemispherx Europe, cleared the first stage of [...]

Published
2000

9. Hemispherx Biopharma Inc

Author

George, John

Subjects
HemispheRx BioPharma Inc. -- Product development, Bioclones Ltd. -- Product development, Drugs -- Product development, Pharmaceutical industry -- Product development, Business, Business, regional
Abstract

Philadelphia-based Hemispherx Biopharma Inc. announced its licensing partner, Bioclones Ltd. of South Africa, has initiated clinical trials in Africa testing Ampligen as a treatment of severe chronic fatigue syndrome [...]

Published
2000

10. Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis

Subjects
HemispheRx BioPharma Inc. -- Product development, Multiple sclerosis, Biological products industry -- Product development, Banking, finance and accounting industries, Business, Ampligen (Medication)
Abstract

PHILADELPHIA, Sep 23, 2015 (GLOBE NEWSWIRE via COMTEX) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a new peer reviewed article, with senior authors from the Italian Ministry of Health and [...]

Published
2015

11. Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome (CFS) Patients Potentially Predictive of Improved Response to Ampligen

Subjects
HemispheRx BioPharma Inc. -- Product development, Chronic fatigue syndrome, Medical research, Biological products industry -- Product development, Banking, finance and accounting industries, Business, Alferon N (Medication), Ampligen (Medication)
Abstract

PHILADELPHIA, Sep 21, 2015 (GLOBE NEWSWIRE via COMTEX) -- Hemispherx Biopharma (NYSE MKT:HEB) announces the publication of an online peer reviewed research article of an analysis of clinical data on [...]

Published
2015

12. FDA stalls Hemispherx drug vote

Author

George, John

Subjects
United States. Food and Drug Administration -- Powers and duties, HemispheRx BioPharma Inc. -- Product development, Drugs -- Licensing, certification and accreditation, Pharmaceutical industry -- Product development, Business, Business, regional, Ampligen (Medication) -- Licensing, certification and accreditation
Abstract

The Food and Drug Administration extends its assessment of Hemispherx BioPharma's Ampligen due to a rise in workload. Ampligen is a therapeutic compound that has a potential of treating diseases such as the avian flu, cancer, and AIDS. The development of the new medication, which has expanded to over three decades is discussed.

Published
2009

13. Hemispherx Gets FDA Nod for Expansion of Ampligen/FluMist Intranasal Clinical Trial; Stock Soaring in Pre-Market

Subjects
United States. Food and Drug Administration, HemispheRx BioPharma Inc. -- Product development, Stocks -- Prices and rates, Business, Ampligen (Medication)
Abstract

Boston, Dec 09, 2013 (MidnightTrader via COMTEX) -- Shares of Hemispherx BioPharma, Inc. (HEB) climbed almost 73% before opening bell Monday after the specialty pharmaceutical company reported that the U.S. [...]

Published
2013

14. FDA Authorizes Expansion of Ampligen/FluMist Intranasal Clinical Trial Designed to Elicit Potential Protection Against Many Pre-Pandemic Influenza Viruses

Subjects
United States. Food and Drug Administration, HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Influenza viruses, Influenza, Clinical trials, Vaccines -- Product development, Banking, finance and accounting industries, Business, Alferon N (Medication), Ampligen (Medication)
Abstract

PHILADELPHIA, Dec 09, 2013 (GLOBE NEWSWIRE via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the 'Company' or 'Hemispherx') today announced that its Phase 1/2 clinical trial at the University of [...]

Published
2013

15. Hemispherx Biopharma (HEB) release: FDA authorizes expansion of ampligen/flumist intranasal clinical trial designated to elicit potential protection against many pre-pandemic influenza viruses

Subjects
United States. Food and Drug Administration, HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Influenza viruses, Influenza, Clinical trials, Vaccines -- Product development, Business, Chemicals, plastics and rubber industries
Abstract

On 9 Dec 2013, Hemispherx Biopharma Inc announced that its phase 1/2 clinical trial at the University of Alabama Vaccine Research Clinic is being expanded based on an analysis of [...]

Published
2013

16. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc

Subjects
United States. Food and Drug Administration, HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Securities fraud, Class actions (Civil procedure), Drug approval, Business, News, opinion and commentary, Ampligen (Medication)
Abstract

SAN DIEGO and PHILADELPHIA, Jan. 17, 2013 /PRNewswire/ -- http://www.robbinsarroyo.com/about-us/ at Robbins Arroyo LLP announce that purchasers of Hemispherx Biopharma, Inc. (NYSE: HEB)('Hemispherx' or the 'Company') have filed a complaint [...]

Published
2013

17. FDA Panel considers 1st drug for chronic fatigue syndrome; only some patients got relief from the experimental treatment, experts say

Author

Reinberg, Steven

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological response modifiers -- Licensing, certification and accreditation, Pharmaceutical industry -- Product development, Health, Ampligen (Medication) -- Licensing, certification and accreditation
Abstract

Byline: Steven Reinberg, HealthDay Reporter THURSDAY, Dec. 20 (HealthDay News) -- A U.S. Food and Drug Administration advisory committee will meet Thursday to consider approval of the first drug to [...]

Published
2012

18. Hemispherx BioPharma, FDA Reach Agreement on Filing Requirements for Ampligen New Drug Application; Shares Soar 41.1% Toward Year High

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Stocks -- Prices and rates, Business, Ampligen (Medication)
Abstract

Boston, Jul 11, 2012 (MidnightTrader via COMTEX) -- Hemispherx BioPharma, Inc. (HEB) hit a day's high of $0.43 this morning, currently up 41.1% at $0.40 after the company detailed its [...]

Published
2012

19. Hemispherx Biopharma and the FDA reach agreement on filing requirements for the company's Complete Response in support of Ampligen New Drug Application for Chronic Fatigue Syndrome treatment

Subjects
United States. Food and Drug Administration, HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Chronic diseases, Chronic fatigue syndrome, Business, Chemicals, plastics and rubber industries
Abstract

Hemispherx Biopharma Inc (Hemispherx) recently met with representatives of the US Food and Drug Administration (the FDA). At that meeting, the FDA agreed to accept, for review, new analyses of [...]

Published
2012

20. Hemispherx Biopharma and the FDA Reach Agreement on Filing Requirements for the Company's Complete Response in Support of Ampligen(R) New Drug Application for Chronic Fatigue Syndrome Treatment

Subjects
United States. Food and Drug Administration, HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Chronic diseases, Chronic fatigue syndrome, Banking, finance and accounting industries, Business, Ampligen (Medication)
Abstract

Byline: Staff PHILADELPHIA, Jul 11, 2012 (GlobeNewswire via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the 'Company' or 'Hemispherx') recently met with representatives of the U.S. Food and Drug Administration (the [...]

Published
2012

21. FDA authorises new Hemispherx Biopharma (HEB) clinical trial of intranasal Ampligen with seasonal influenza vaccine

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Influenza vaccines -- Product development, Influenza -- Drug therapy, Clinical trials, Business, Chemicals, plastics and rubber industries, Ampligen (Medication)
Abstract

Hemispherx Biopharma Inc has received US Food Drug Administration (FDA) authorisation to proceed with the initiation of a new clinical trial of intranasal Ampligen [rintatolimod; poly(I)DTpoly(C12,U)] used in conjunction with [...]

Published
2011

22. FDA Authorizes New Hemispherx Biopharma Clinical Trial of Intranasal Ampligen(R) With Seasonal Influenza Vaccine

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Influenza vaccines -- Product development, Influenza -- Drug therapy, Clinical trials, Banking, finance and accounting industries, Business, Ampligen (Medication)
Abstract

Byline: Staff PHILADELPHIA, Jul 20, 2011 (GlobeNewswire via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the 'Company' or 'Hemispherx') today announced it has received U.S. Food Drug Administration (FDA) authorization [...]

Published
2011

23. Quest PharmaTech announces clinical development agreement with Hemispherx Biopharma Inc to evaluate a combinatorial immunotherapy technology

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Immunotherapy, Business, Chemicals, plastics and rubber industries
Abstract

Quest PharmaTech Inc (Quest) announced a clinical development arrangement with US based Hemispherx Biopharma Inc (Hemispherx) to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune [...]

Published
2011

24. Ampligen

Subjects
HemispheRx BioPharma Inc. -- Product development, Immunosuppressive agents -- Licensing, certification and accreditation, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Ampligen (Medication) -- Licensing, certification and accreditation
Abstract

Rintatolimod (Ampligen, Hemispherx Biopharma) for chronic fatigue syndrome (CFS). FDA said Hemispherx should conduct at least 1 additional clinical trial, complete various nonclinical studies, and perform a number of data [...]

Published
2013

25. Hemispherx Biopharma prepares application to initiate Phase II clinical trials in China with Ampligen

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Clinical trials, Business, Chemicals, plastics and rubber industries
Abstract

As part of its expanding international programme, Hemispherx Biopharma Inc (Hemispherx) announced an agreement with Fountain Medical Development Ltd (Fountain Medical), a leading Chinese clinical research organization (CRO) to prepare, [...]

Published
2010

26. Hemispherx Biopharma Prepares Application to Initiate Phase II Clinical Trials in China With Ampligen(R)

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Medical research, Medicine, Experimental, Clinical trials, Banking, finance and accounting industries, Business, Ampligen (Medication)
Abstract

Byline: Staff PHILADELPHIA, May 17, 2010 (GlobeNewswire via COMTEX) -- As part of its expanding international program Hemispherx Biopharma, Inc. (NYSE Amex:HEB), (the 'Company'), announced an agreement with Fountain Medical [...]

Published
2010

27. New Independent Data Monitoring Committee Established by Hemispherx to Accelerate Global Drug Development

Subjects
HemispheRx BioPharma Inc. -- Product development, Medical research, Medicine, Experimental, Pharmaceutical industry -- Product development, Banking, finance and accounting industries, Business, Alferon N (Medication)
Abstract

Byline: Staff PHILADELPHIA, May 3, 2010 (GlobeNewswire via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE AMEX:HEB) (the 'Company') announced today the formation of an Independent Data Monitoring Committee (DMC) which will [...]

Published
2010

28. Hemispherx Biopharma's Ampligen NDA for Chronic Fatigue Syndrome Accepted for Review by the FDA; Marks the First Drug Candidate for Approval to Treat CFS, and the First Compound in the TLR Class

Subjects
HemispheRx BioPharma Inc. -- Product development, Chronic fatigue syndrome -- Drug therapy, Biological products industry -- Product development, Pharmaceutical industry -- Product development, Drug approval, Banking, finance and accounting industries, Business, Ampligen (Medication)
Abstract

PHILADELPHIA, Jul 8, 2008 (PrimeNewswire via COMTEX) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today reported that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's New Drug [...]

Published
2008

29. Hemispherx Biopharma, Inc. Completes Enrollment in Phase II Study of Ampligen as Seasonal Flu Vaccine Enhancer; Six-Month Study Will Also Assess Potential Cross-Protection Against H5N1 Avian Influenza

Subjects
HemispheRx BioPharma Inc. -- Product development, Avian influenza, Biological products industry -- Product development, Medical research, Medicine, Experimental, Influenza vaccines -- Product development, Clinical trials, Banking, finance and accounting industries, Business, Ampligen (Medication) -- Product development
Abstract

Byline: Staff PHILADELPHIA, Jun 2, 2008 (PrimeNewswire via COMTEX) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today reported that it has completed enrollment in a Phase II clinical trial to evaluate the [...]

Published
2008

30. Hemispherx Biopharma Initiates Phase IIb Trial in Australia for Ampligen as Vaccine Adjuvant for Seasonal Influenza

Subjects
HemispheRx BioPharma Inc. -- Product development, Vaccines -- Product development, Biological products industry -- Product development, Influenza, Clinical trials, Business, Business, international, Ampligen (Medication)
Abstract

...Goal is to Evaluate Immune Augmentation and Possible Cross-Protection by TLR Ligand Ampligen([R]) SYDNEY, Australia -- Hemispherx Biopharma, Inc. (AMEX: HEB) announced the initiation of a well-controlled Phase IIb trial [...]

Published
2007

31. Ampligen & chronic fatigue

Author

Klotter, Jule

Subjects
HemispheRx BioPharma Inc. -- Product development, Pharmaceutical industry -- Product development, Health, Ampligen (Medication) -- Testing -- Product development
Abstract

Hemispherx Biopharma, Inc. has completed a Phase III Chronic Fatigue Syndrome (CFS) trial of Ampligen, a double-stranded RNA drug. In vitro studies indicate that Ampligen may modulate the immune system [...]

Published
2005

32. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc

Subjects
United States. Food and Drug Administration, HemispheRx BioPharma Inc. -- Product development, Securities fraud, Biological products industry -- Product development, Class actions (Civil procedure), Health, Ampligen (Medication)
Abstract

By a News Reporter-Staff News Editor at Clinical Trials Week -- Shareholder rights attorneys at Robbins Arroyo LLP announce that purchasers of Hemispherx Biopharma, Inc. (NYSE: HEB) ('Hemispherx' or the [...]

Published
2013

33. Hemispherx Biopharma, Inc

Subjects
HemispheRx BioPharma Inc. -- Product development, Antiviral agents -- Evaluation -- Product development, Anti-HIV agents -- Evaluation, Pharmaceutical industry -- Product development, General interest, Health, Evaluation, Product development
Abstract

Phase 2 Most recent data of the Hemispherx Biopharma, Inc. (Philadelphia, PA) Phase 2b clinical trial, AMP 720, was reported. Using Strategic Treatment Interruption (STI), subjects' antiviral HAART regimens are [...]

Published
2003

34. Quest PharmaTech Announces Clinical Development Agreement with Hemispherx Biopharma Inc. to evaluate a combinatorial Immunotherapy Technology

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Homeopathy -- Materia medica and therapeutics, Immunotherapy, Drugs -- Product development, Therapeutics -- Product development, Cancer -- Care and treatment, Health
Abstract

Quest PharmaTech Inc. (TSX-V: QPT) ('Quest' or the 'Company'), a pharmaceutical company developing and commercializing products for the treatment of cancer, announced a clinical development arrangement with U.S. based Hemispherx [...]

Published
2011

35. Hemispherx Expands Phase III CFS Trial; 4th Center Contracts to Enroll Ampligen(R) Patients

Subjects
HemispheRx BioPharma Inc. -- Product development, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

NEW YORK, Oct. 28 /PRNewswire/ -- Hemispherx Biopharma (Amex: HEB) said today that it completed contractual arrangements with the fourth site that will begin enrolling patients in a Phase III [...]

Published
1998

36. Hemispherx: New Clinical Data in Ongoing CFS Treatment Program

Subjects
HemispheRx BioPharma Inc. -- Product development, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

New Data Through mid-1998 Compared with Historic Baselines NEW YORK, Oct. 19 /PRNewswire/ -- Hemispherx Biopharma (Amex: HEB), today released additional data from its ongoing Phase II clinical trials with [...]

Published
1998

37. Hemispherx Announces New Studies on Ampligen Safety

Subjects
HemispheRx BioPharma Inc. -- Product development, Biotechnology industry -- Product development, Business, News, opinion and commentary
Abstract

NEW YORK, Oct. 14 /PRNewswire/ -- Hemispherx Biopharma (Amex: HEB) today announced the completion of four new animal studies on the safety of its developmental drug Ampligen, which will be [...]

Published
1998

39. New Diagnostic Marker for CFS

Subjects
HemispheRx BioPharma Inc. -- Product development, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

May Provide First Evidence of Specific Biochemical Probe Correlating with CFS Disease Severity as Well as the Recovery Steps NEW YORK, Oct. 9 /PRNewswire/ -- HEMISPHERX BIOPHARMA (Amex: HEB) stated [...]

Published
1998

40. Ampligen In Clinical Trial Treating HIV Patients In Texas

Subjects
HemispheRx BioPharma Inc. -- Product development, Biotechnology industry -- Product development, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

PHILADELPHIA--(HealthWire)--January 13, 1996--HEMISPHERx BIOPHARMA INC. (NASDAQ: HEMX, HEMXW) announced today that they had begun a new Phase II clinical trial in Texas treating HIV infected patients with the Company's proprietary [...]

Published
1997

41. Hemispherx to expand CFS program

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, HemispheRx BioPharma Inc. -- Product development, Pharmaceutical industry -- Product development, Business, Pharmaceuticals and cosmetics industries, Retail industry, Ampligen (Medication) -- Product development
Abstract

Hemispherx Biopharma Inc. has received authorization from the FDA to more than double the number of patients undergoing treatment in its program for chronic fatigue syndrome. The action means that [...]

Published
1999

42. HEMISPHERx Announces European Patent Approval of CFS Diagnostic

Subjects
HemispheRx BioPharma Inc. -- Product development, Medical equipment and supplies industry -- Product development, Business, Business, international
Abstract

PHILADELPHIA, PA--(HealthWire)--December 6, 1996-- Diagen(R) is First Chronic Fatigue Syndrome Diagnostic HEMISPHERx BIOPHARMA, INC. (NASDAQ: HEMX) today announced that it received patent approval on its Chronic Fatigue Syndrome (CFS) diagnostic, [...]

Published
1996

43. Ampligen trial of CFS patients in Belgium shows significant improvements

Subjects
HemispheRx BioPharma Inc. -- Product development, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

SAN FRANCISCO--(HealthWire)--Oct. 15, 1996-- No evidence of significant toxicities Results of a Belgium clinical study presented today at the annual scientific meeting of the American Association for Chronic Fatigue Syndrome [...]

Published
1996

44. CANADA AUTHORIZES FIRST IMMUNE-BASED DRUG FOR HIV

Subjects
HemispheRx BioPharma Inc. -- Product development, Pharmaceutical industry -- Product information, Business, News, opinion and commentary
Abstract

PHILADELPHIA, May 16 /PRNewswire/ -- HemispheRx Biopharma Inc. (Nasdaq: HEMXU) announced today that Helix Biopharma Corp of British Columbia, Canada, has been authorized to supply Ampligen(R) under the Emergency Drug [...]

Published
1996

45. HEMISPHERX RECEIVES EUROPEAN PATENTS FOR NUCLEIC ACID DRUG TECHNOLOGY

Subjects
HemispheRx BioPharma Inc. -- Product development, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

PHILADELPHIA, April 22 /PRNewswire/ -- HemispheRx Biopharma, Inc. (Nasdaq: HEMXU) announced today receipt of a broad group of new patent approvals from examiners representing the European Patent Organization (EPO). These [...]

Published
1996

46. HEMISPHERX COMPLETES ENROLLMENT IN PHASE II AMPLIGEN STUDY

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Avian influenza -- Research, Medical research, Medicine, Experimental, Influenza vaccines -- Research -- Product development, Clinical trials -- Research, Biotechnology industry, Business, Ampligen (Medication) -- Research -- Product development
Abstract

Hemispherx Biopharma, Inc. Completes Enrollment in Phase II Study of Ampligen as Seasonal Flu Vaccine Enhancer Six-Month Study Will Also Assess Potential Cross-Protection Against H5N1 Avian Influenza Hemispherx Biopharma, Inc. [...]

Published
2008

47. HEMISPHERX INITIATES AMPLIGEN PHASE IIB FOR INFLUENZA

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Influenza, Clinical trials, Biotechnology industry, Business, Ampligen (Medication) -- Product development
Abstract

Hemispherx Biopharma, Inc. (AMEX: HEB), has initiated a well- controlled Phase IIb trial in Australia of Ampligen(r), an experimental TLR3 ligand shown to function as an immune system activator , [...]

Published
2007

48. Clinical trials update

Subjects
Orphan Medical Inc. -- Product development -- 00346305, PHYTOpharmaceuticals Inc. -- Product development -- 00275726, Eli Lilly and Co. -- Product development -- 00305219, CytRx Corp. -- Product development -- 00322907, North American Biologicals Inc. -- Product development -- 00306356, HemispheRx BioPharma Inc. -- Product development, Pharming -- Product development, Pharmaceutical industry -- Product development, Biotechnology industry -- Product development, Business, Pharmaceuticals and cosmetics industries
Published
1998

49. Hemispherx announces influenza vaccine/immunopotentiation clinical trials

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Influenza vaccines -- Product development, Drugs -- Product development, Influenza, Clinical trials, Health, Science and technology, Product development
Abstract

Hemispherx Biopharma, Inc., (HEB) announced that it has procured the seasonal influenza vaccine it needs to execute a well-controlled (placebo vs. Ampligen) immunopotentiation clinical trial. This phase II clinical trial [...]

Published
2006

50. Hemispherx announces influenza vaccine/immunopotentiation clinical trials

Subjects
Biological products industry -- Product development, Influenza vaccines -- Product development, Influenza, Drugs -- Product development, Clinical trials, HemispheRx BioPharma Inc. -- Product development
Abstract

Hemispherx Biopharma, Inc., (HEB) announced that it has procured the seasonal influenza vaccine it needs to execute a well-controlled (placebo vs. Ampligen) immunopotentiation clinical trial. This phase II clinical trial [...]

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results